AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 31862447
Drug: Surgical procedure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical procedure for treatment of intermittent exotropia in children aged 3 to <5 years.
Trial: 31862447
Drug: Surgical procedure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical procedure for treatment of intermittent exotropia in children aged 5 to <11 years.
Trial: 31509993
Drug: Human Animal
RxNorm normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Human Animal Interaction with therapy dogs only (100% HAI)
Trial: 27339738
Drug: obinutuzumab or
RxNorm normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: obinutuzumab or rituximab induction therapy (IT) for 4 weeks
Trial: 9508174
Drug: i.t. methotrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.t. methotrexate (MTX) and cranial radiation therapy (CRT) (regimen A, n = 317)
Trial: 9419751
Drug: DHEA infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA infusion (1 mg/hour for 17 hours)
Trial: 1915209
Drug: Caffeine (3.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (3.3 mg/kg, equivalent to 2 to 3 cups of coffee)
Trial: 8420868
Drug: Misonidazole combined
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Misonidazole combined with radiation therapy
Trial: 8420868
Drug: Cranial treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cranial treatment responders
Trial: 321177
Drug: Naproxen (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen (300 or 600 mg)
Trial: 321177
Drug: Naproxen sodium
RxNorm normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naproxen sodium (275 mg)
Trial: 31736077
Drug: Morus nigra
RxNorm normalized name: MORUS NIGRA ROOT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morus nigra L. (MN) leaf powder 250 mg for 60 days
Trial: 31736077
Drug: Hormone therapy
RxNorm normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hormone therapy (HT) 1 mg estradiol for 60 days
Trial: 25586298
Drug: ropinirole prolonged
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ropinirole prolonged release (PR) administered for 24 weeks as adjunctive to levodopa
Trial: 30589922
Drug: Dexamethasone implant
RxNorm normalized name: dexamethasone Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone implant after switching from aflibercept
Trial: 25695576
Drug: Perioperative smoking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perioperative smoking cessation intervention (brief counseling, brochures, referral to quitline, 6-week transdermal nicotine replacement)
Trial: 21525768
Drug: Synbiotics (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synbiotics (1 g of Bifidobacterium breve strain Yakult three times a day and 5.5 g of GOS once a day for one year)
Trial: 17892374
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid 5 mg intravenously once yearly
Trial: 16490030
Drug: Aggressive diabetes
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aggressive diabetes mellitus treatment and good glycemic control
Trial: 11228790
Drug: Anxiolytic premedication
RxNorm normalized name: ANXIOLYTICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anxiolytic premedication (midazolam 7.5 mg, midazolam 15 mg, diazepam 15 mg)
Trial: 8044953
Drug: Intravenous pentoxifylline
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous pentoxifylline (200 mg over 2 hours BID) with intensive vascular training
Trial: 8044953
Drug: Intravenous prostaglandin
RxNorm normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous prostaglandin E1 (40 micrograms over 2 hours BID) with intensive vascular training
Trial: 30755171
Drug: Modified full
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified full enteral nutrition (standard full EN in conjunction with prokinetic drug)
Trial: 25163498
Drug: 30 g
RxNorm normalized name: Lancet Unilet 30 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 g of roasted flaxseed powder for 3 months
Trial: 23095069
Drug: Professional oral
RxNorm normalized name: Dentek Professional Oral Care Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Professional oral health care (POHC) treatment by dental hygienists (n = 21)
Trial: 19380445
Drug: PCI(10) and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCI(10) and PCI(20) - combination of CP-751,871 (10 to 20 mg/kg), paclitaxel (200 mg/m²), and carboplatin (AUC 6) every 3 weeks for up to six cycles.
Trial: 7562288
Drug: Amoxicillin prophylaxis
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin prophylaxis
Trial: 11965280
Drug: Vitamin A
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin A supplementation with measles vaccine
Trial: 2219758
Drug: Aspirin with
RxNorm normalized name: Bayer Aspirin with Calcium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin with dipyridamol
Trial: 28423174
Drug: Propranolol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (2 mg/kg/d) for 16 weeks
Trial: 28423174
Drug: Steroid (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid (2 mg/kg/d) for 16 weeks
Trial: 15579519
Drug: Higher hemoglobin
RxNorm normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher hemoglobin targets (> 130 g/L)
Trial: 15579519
Drug: Lower hemoglobin
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower hemoglobin targets (< 120 g/L)
Trial: 11954942
Drug: Quinapril treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinapril treatment
Trial: 11179530
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no quinapril treatment)
Trial: 9751014
Drug: End-of-treatment HCV
RxNorm normalized name: End-Zit
DrugBank: Octasulfur (DB09353)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: End-of-treatment HCV RNA response
Trial: 1884902
Drug: Cyclosporin A
RxNorm normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporin A (CsA) treatment for a mean of 13.8 months
Trial: 1884902
Drug: Cyclosporin A
RxNorm normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporin A (CsA) treatment
Trial: 30958508
Drug: Rivaroxaban (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban (15 mg per day)
Trial: 22883004
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy of valproic acid (VPA) and lamotrigine (LTG)
Trial: 20417262
Drug: 13-valent pneumococcal
RxNorm normalized name: Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine
DrugBank: Streptococcus pneumoniae type 14 capsular polysaccharide diphtheria CRM197 protein conjugate antigen (DB10289)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 13-valent pneumococcal conjugate vaccine (PCV13) and 7-valent pneumococcal conjugate vaccine (PCV7)
Trial: 14694970
Drug: Intracervical PGE2
RxNorm normalized name: PGE2
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intracervical PGE2 (dinoprostone 0.5 mg) by gel (n = 66)
Trial: 14694970
Drug: Intravaginal PGE2
RxNorm normalized name: PGE2
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravaginal PGE2 (dinoprostone 10 mg) by pessary (n = 49)
Trial: 14694970
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (gel and pessary)
Trial: 9335389
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil (MMF) 2-g treatment group
Trial: 9335389
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (quadruple sequential induction therapy)
Trial: 8254147
Drug: Fluoxetine and
RxNorm normalized name: fluoxetine and psycholeptics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine and Amitriptyline
Trial: 2871486
Drug: Control immunosuppressive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control immunosuppressive therapy (azathioprine and prednisone, with or without antilymphocyte globulin)
Trial: 30129417
Drug: Topical simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical simvastatin 1% topical solution
Trial: 30129417
Drug: Oral simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral simvastatin 20mg/day
Trial: 27665525
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (proton pump inhibitor, amoxicillin 1000mg, clarithromycin 500mg or metronidazole 400mg, given twice daily for 7-14 days)
Trial: 27665525
Drug: Sequential therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential therapy (PPI twice daily for 10 days, amoxicillin 1000mg twice daily for the first 5 days, followed by clarithromycin 500mg and metronidazole 400mg twice daily for the subsequent 5 days)
Trial: 22578530
Drug: Brief Motivational
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brief Motivational Intervention for at-risk drinking (BMI-ETOH) among Hispanics with drug dependence
Trial: 15302787
Drug: High-dose sirolimus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose sirolimus (24 mg loading dose, 2 mg/d for 7 days)
Trial: 15302787
Drug: Usual-dose sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Usual-dose sirolimus (8 mg loading dose, 2 mg/d for 7 days)
Trial: 8123267
Drug: Thiopental sodium
RxNorm normalized name: Thiopental Sodium
DrugBank: Thiopental (DB00599)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Thiopental sodium 4 mg/kg i.v., followed by 0.5% to 1.5% enflurane and 67% N2O in O2 (Group 1)
Trial: 8123267
Drug: Propofol 2
RxNorm normalized name: propofol 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 2 mg/kg i.v., followed by 0.5% to 1.5% enflurane and 67% N2O in O2 (Group 2)
Trial: 8123267
Drug: Propofol 2
RxNorm normalized name: propofol 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 2 mg/kg i.v., followed by propofol 50 to 160 micrograms/kg/min i.v. and 67% N2O in O2 (Group 3)
Trial: 3322358
Drug: Captopril 25
RxNorm normalized name: captopril 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 25 mg, three times daily for 6 weeks
Trial: 31115667
Drug: Supervised low-intensity
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised low-intensity cycling for 20 minutes during chemotherapy infusion
Trial: 31115667
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care during chemotherapy infusion
Trial: 26600017
Drug: Baseline serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline serum magnesium (Mg) increase of 0.1 mmol/L
Trial: 26600017
Drug: Baseline serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline serum magnesium (Mg) levels over time
Trial: 23329358
Drug: High-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy alone
Trial: 23329358
Drug: High-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy with total body irradiation
Trial: 18345709
Drug: Recombinant factor
RxNorm normalized name: Recombinant factor IX
DrugBank: Coagulation Factor IX (Recombinant) (DB00100)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant factor VIIa (270 microg/kg dose)
Trial: 3663564
Drug: oral nadolol
RxNorm normalized name: Nadolol
DrugBank: Nadolol (DB01203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral nadolol 20 mg once daily
Trial: 3663564
Drug: topical timolol
RxNorm normalized name: timolol
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: topical timolol 0.25% twice daily
Trial: 16146905
Drug: Complete multivessel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complete multivessel treatment
Trial: 16146905
Drug: Culprit lesion
RxNorm normalized name: scabies lesion lysate (human)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Culprit lesion treatment only
Trial: 8422661
Drug: Selegiline 5
RxNorm normalized name: selegiline 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selegiline 5 mg daily
Trial: 8422661
Drug: Selegiline 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selegiline 10 mg daily
Trial: 9159721
Drug: Selegiline 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selegiline 20 mg weekly (10 mg x 2)
Trial: 9159721
Drug: Selegiline 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selegiline 10 mg weekly
Trial: 26056856
Drug: Individualised lower
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualised lower limb progressive resistance training programme (twice a week for 12 weeks)
Trial: 20947887
Drug: LV5FU2-CDDP as
RxNorm normalized name: CDDP
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: LV5FU2-CDDP as first-line treatment
Trial: 12577231
Drug: Gemcitabine as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine as first-line treatment
Trial: 17767800
Drug: Isoflavones (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoflavones (50 mg of daidzein and genistein)
Trial: 12651635
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid 30 mg/kg
Trial: 8857512
Drug: High PNG
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High PNG diet (1.52 mg/d of vitamin B-6, 27% PNG)
Trial: 8857512
Drug: Low PNG
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low PNG diet (1.44 mg/d of vitamin B-6, 9% PNG)
Trial: 1509190
Drug: Almitrine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almitrine (100 mg per day)
Trial: 6476299
Drug: Buprenorphin sublingual
RxNorm normalized name: buprenorphine Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphin sublingual (0.4 mg.)
Trial: 6476299
Drug: Pentazocin i.m.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentazocin i.m. (30 mg.)
Trial: 29937430
Drug: sotagliflozin 200
RxNorm normalized name: sotagliflozin 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sotagliflozin 200 mg
Trial: 24983260
Drug: Heparin flushing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin flushing protocol
Trial: 22128082
Drug: High-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intravenous cyclophosphamide (ivCY)
Trial: 21284283
Drug: CT gel
RxNorm normalized name: PROSOURCE GELATEIN PLUS LIME W/MCT GEL,ORAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT gel (clindamycin phosphate 7.2% - tretinoin 0.025%) + BPO wash 4%
Trial: 21284283
Drug: CT gel
RxNorm normalized name: PROSOURCE GELATEIN PLUS LIME W/MCT GEL,ORAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT gel (clindamycin phosphate 7.2% - tretinoin 0.025%) + SFC (nonmedicated soap-free cleanser)
Trial: 17272314
Drug: Glucose-added bicarbonate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose-added bicarbonate solution (90 mg/dl)
Trial: 17272314
Drug: Glucose-free bicarbonate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose-free bicarbonate solution
Trial: 15121352
Drug: Antipsychotic continuation
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotic continuation
Trial: 15121352
Drug: Taper to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taper to placebo
Trial: 3192904
Drug: Endotelon (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endotelon (4 tablets of 50 mg per day for five weeks)
Trial: 31773485
Drug: Zinc glycine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc glycine chelate (ZnG) at 90 mg Zn/kg
Trial: 30213583
Drug: Topical steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical steroid treatment for 8 weeks
Trial: 18450903
Drug: Needle-free powder
RxNorm normalized name: acid red 337 free acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Needle-free powder lidocaine delivery system (0.5 mg of lidocaine)
Trial: 21346100
Drug: Caffeinated coffee
RxNorm normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeinated coffee (3 mg caffeine/kg body weight)
Trial: 19596139
Drug: CA-125 >35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CA-125 >35 U/ml
Trial: 2793338
Drug: Shift in
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Shift in treatment
Trial: 21993153
Drug: Brief transdiagnostic
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brief transdiagnostic internet treatment (Wellbeing Program)
Trial: 20186639
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (self-monitoring daily pedometer step count)
Trial: 2894904
Drug: Terfenadine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terfenadine (60 mg b.i.d.)
Trial: 11325074
Drug: ACE inhibitor
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitor (benazepril at a dose of 2.5 mg daily)
Trial: 11325074
Drug: Alphabeta blocker
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alphabeta blocker (arotinolol at a dose of 20 mg daily)
Trial: 7956637
Drug: Normal urinary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal urinary albumin excretion (UAE)
Trial: 3791141
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment with chemotherapy and intensive meningeal radiotherapy (vincristine, actinomycin D, cyclophosphamide, Adriamycin, 4000 to 5500 rad radiation therapy, intrathecal drugs)
Trial: 3791141
Drug: Preintensive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preintensive treatment with chemotherapy and nonintensive meningeal radiotherapy (vincristine, actinomycin D, 4000 to 5500 rad radiation therapy)
Trial: 3791141
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment group (within group analysis)
Trial: 24022862
Drug: Aspirin (81
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (81 mg daily for 7 days)
Trial: 10410527
Drug: Aquatic exercises
RxNorm normalized name: Mentha aquatica leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aquatic exercises (frequency: once a week, twice a week, or 3 or more times a week)
Trial: 7772012
Drug: medroxyprogesterone acetate
RxNorm normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: medroxyprogesterone acetate 2.5 mg daily
Trial: 7772012
Drug: medroxyprogesterone acetate
RxNorm normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: medroxyprogesterone acetate 5 mg daily
Trial: 7772012
Drug: medroxyprogesterone acetate
RxNorm normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: medroxyprogesterone acetate 10 mg daily
Trial: 7772012
Drug: medroxyprogesterone acetate
RxNorm normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: medroxyprogesterone acetate 2.5 mg, 5 mg, or 10 mg daily
Trial: 7772012
Drug: medroxyprogesterone acetate
RxNorm normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: medroxyprogesterone acetate 5 mg and 10 mg
Trial: 2149046
Drug: Teicoplanin as
RxNorm normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teicoplanin as first-line treatment
Trial: 2149046
Drug: Teicoplanin as
RxNorm normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teicoplanin as second-line therapy
Trial: 23537687
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (solifenacin plus tamsulosin OCAS)